When should JAK inhibitors be used in a patient with interstitial lung disease who has failed conventional disease‑modifying agents and has stable lung function?

When to Use JAK Inhibitors in Interstitial Lung Disease

For patients with inflammatory myopathy-associated ILD (IIM-ILD) who have failed conventional DMARDs with stable lung function, JAK inhibitors are conditionally recommended as a treatment option, whereas for other types of systemic autoimmune rheumatic disease-associated ILD (SARD-ILD), JAK inhibitors should generally be avoided unless the patient has IIM-ILD. 1

Disease-Specific Recommendations

First-Line Use (IIM-ILD Only)

• JAK inhibitors are conditionally recommended as first-line treatment specifically for IIM-ILD 1
• For all other SARD-ILD subtypes (including RA-ILD, SSc-ILD, SjD-ILD, MCTD-ILD), JAK inhibitors are conditionally recommended against as first-line therapy 1

Second-Line Use After Treatment Failure

For IIM-ILD with disease progression:

• JAK inhibitors are conditionally recommended when first-line therapy fails 1
• They are preferred over azathioprine in this setting 1

For other SARD-ILD types:

• After failure of first-line agents (mycophenolate, rituximab, cyclophosphamide), the evidence is more nuanced
• Recent observational data in RA-ILD suggests JAK inhibitors may stabilize or improve lung function (mean increase of 2.07% in FVC and 3.12% in DLCO) 2
• They show comparable efficacy to abatacept and rituximab for RA-ILD 2, 3

Clinical Context for Your Patient

Given your patient has:

• Stable lung function (not progressive disease)
• Failed conventional DMARDs
• Unspecified SARD-ILD type

If the patient has IIM-ILD:

JAK inhibitors are an appropriate option now, either as monotherapy or added to existing therapy 1

If the patient has RA-ILD:

• JAK inhibitors can be considered based on emerging evidence showing safety and efficacy comparable to rituximab and abatacept 4, 2, 3
• Recent real-world data (2024-2026) supports their use in RA-ILD with stable disease 5, 6
• The 24-month retention rate is approximately 42%, with ILD remaining stable in 69% of patients 5

If the patient has SSc-ILD, SjD-ILD, or MCTD-ILD:

JAK inhibitors are not recommended based on current guidelines 1

Important Safety Considerations

Critical caveats when using JAK inhibitors in ILD:

• Age and cardiovascular risk: Recent real-world data suggest higher mortality risk compared to TNF inhibitors in older patients or those with cardiovascular comorbidities 7
• Infection risk: Clinically significant infections occur in 4.5-25% of cases 2
• Respiratory infections: 38% incidence in one cohort, though most were manageable 5
• Acute exacerbations: Rare but serious; interestingly, discontinuation of JAK inhibitors may precipitate acute exacerbation (median 9 days post-discontinuation in one series) 8

Monitoring Requirements

When initiating JAK inhibitors in ILD patients:

• Baseline: CBC, comprehensive metabolic panel, lipids, hepatitis B/C screening, TB screening
• Follow-up: CBC every 2-4 months, liver function tests monthly initially then every 3 months
• Pulmonary monitoring: FVC and DLCO at 6-month intervals; HRCT as clinically indicated 1

Practical Algorithm

1. Confirm ILD subtype (IIM-ILD vs. other SARD-ILD)
2. If IIM-ILD: JAK inhibitors are guideline-supported now
3. If RA-ILD: Consider JAK inhibitors as equivalent alternative to rituximab/abatacept based on recent evidence
4. If SSc-ILD/SjD-ILD/MCTD-ILD: Prioritize mycophenolate, rituximab, cyclophosphamide, or nintedanib (for SSc-ILD) instead
5. Screen for cardiovascular risk factors and age >65 before initiating
6. Methotrexate co-administration is optional and does not significantly impact ILD outcomes 6

The evidence quality is very low across all recommendations, reflecting the limited randomized trial data in this population 1. However, the convergence of recent observational studies (2024-2026) provides reassuring real-world safety and efficacy data for JAK inhibitors in RA-ILD specifically 4, 2, 3, 5.